Thomson Reuters is the world’s leading provider of intelligent information for businesses and professionals, and our Life Sciences Division supplies thousands of customers with cutting-edge technologies and comprehensive manually curated data resources. For more than 10 years, our team has been at the forefront of the systems biology industry, providing advanced bioinformatics and personalized medicine research and products to pharmaceutical companies, clinical centers and non-profit organizations globally.
We are a multi-disciplinary, diverse group of scientists who enjoy working together and with customers on developing
new technologies, algorithms and solutions. We create and apply state of the art bioinformatics approaches to address real life challenging problems in pharmaceutical R&D, such as drug target identification, biomarker discovery, disease mechanisms understanding, patient stratification and personalized medicine. Leading technologies and creative environment make our team the fastest growing business at Thomson Reuters Life Sciences Division and a key partner for our customers.
We are always looking for talented scientists to grow and develop our team and currently we are looking for an
experienced bioinformatician who will work with our clients, from pharmaceutical companies and clinical centers as well as non-profit organizations, on advanced statistical and functional analysis of OMICs data generating hypotheses on disease mechanisms, disease and drug response biomarkers and drug targets. One of your key areas of focus will be research and development for our personalized medicine technology and solutions. In your projects, you will apply stateof- the-art bioinformatics tools as well as our advanced proprietary Systems Biology Platform; you will also develop new approaches and techniques to address complicated and interesting scientific questions, publish results of your research in scientific journals, and participate in the implementation of the approaches in working tools and commercial software. In addition to research activities, you will also participate in business and strategy development by scoping with customers their scientific needs and transforming these needs into solutions.
Example of on-going research projects:
Drug response biomarker panel development. Development of drug response biomarkers from pre-clinical data is a critical step in drug discovery, as it enables patient stratification in clinical trials design. During the last 3 years, our team is supporting a global oncology company in identification of drug response biomarkers for anti-cancer drugs. The analysis starts with treatment data (IC50), gene expression data, and genetic data for cell lines and is aimed at the identification of biomarkers which are then applied in clinical trials for patient stratification. Our team is responsible for the identification of gene expression and genetic biomarkers for compounds from the company’s portfolio.
Overall, our projects are focused on all stages of the drug development process. Here are some press releases describing our projects
Collaboration with Orion Bionetworks (http://thomsonreuters.com/press-releases/102013/Orion-Bionetworks)
Collaboration with NuMedii (http://thomsonreuters.com/press-releases/112013/NuMedii-Initiative)
What is in it for you?
At Thomson Reuters Systems Biology team, we believe that our scientists are our most important asset and it is our
priority to make it a great place to work.
This position provides unique opportunities for further professional growth:
- enhance your vision and improve your network by working in close collaboration with diverse leading organizations, including pharmaceutical companies, clinical centers and research foundations
- gain unique expertise with internal access to vast data resources at Thomson Reuters, the largest provider of molecular and R&D information in the industry
- extend your technical skills by working in a team of bioinformaticians, biologists, chemists, knowledge management
- specialists and pharmaceutical industry experts with complementary skill sets to address challenges in biomarker
- discovery, target identification, drug repositioning, NGS data analysis, network biology and other applications
- simply enjoy being a part of a global business and a high-performing synergistic team
Qualifications - External
Your Knowledge, Skills, and Abilities
1. Retrieval, statistical analysis, integration, annotation of OMICs data: microarray data, NGS data, proteomics data,
metabolomics data and other types of high-throughput data. Broad experience in statistical analysis and data mining is required.
2. Experience with pathway and network analyses. Integration of multiple complementary OMICs data in the context
of biological pathways and protein interaction networks. Experience with Ingenuity Pathways and MetaCore will be an
3. Proficiency in statistical programming languages (R – required, MatLab – preferred), scripting languages (Perl, Python), database querying languages (SQL)
4. Knowledge of molecular biology, human genetics, normal and pathological signaling pathways is preferred
5. Excellent written and verbal communication skills with the ability to conduct regular presentations and write scientific texts/articles
6. Self starter, able to set priorities and work independently
PhD in Bioinformatics, Statistics, Systems Biology or a related field. A minimum of three to five years of relevant
work experience in bioinformatics or computational biology in professional setting, preferably in a biotechnology,
pharmaceutical, or healthcare setting.
If Interested, please apply here:
Thomson Reuters offers competitive salaries, stock options, vacation, health and dental insurance for employees and their families, life insurance, long term disability and a 401(k) plan.
About Thomson Reuters
Thomson Reuters employees take pride in providing our customers around the world with information that is timely,
accurate, unbiased and trusted. We have a profound respect for the professions and customers we serve and define our success in terms of their success. Our work environment is dynamic, innovative and entrepreneurial. We have a results oriented culture that demands excellence, agility, and the desire to move quickly and precisely to seize opportunities. Our environment is both challenging and supportive - we give employees the opportunity to develop their skills and do their best work.
Thomson Reuters values diversity of culture and thought and seeks talented, qualified employees in all its operations
around the world regardless of race, gender, national origin, religion, sexual orientation, disability, age or any other
protected classification under country or local law.
About the IP & Science Business of Thomson Reuters
The IP & Science business is a global provider of information solutions to assist professionals at every stage of research and development and ensure they maintain and extract maximum value from their intellectual assets.
IP & Science is part of Thomson Reuters www.thomsonreuters.com), the world's leading source of intelligent information for businesses and professionals. Scientific information solutions can be found at thomsonreuters.com.
At Thomson Reuters, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one - collaborating to reach shared goals, and developing through challenging and meaningful experiences. With over 60,000 employees in more than 100 countries, we work flexibly across boundaries and realize innovations that help shape industries around the world. Making this happen is a dynamic, evolving process, and we count on each employee to be a catalyst in driving our performance - and their own.
Thomson Reuters is proud to be an Equal Employment Opportunity/Affirmative Action Employer providing a drug-free workplace.
Intrigued by a challenge as large and fascinating as the world itself? Come join us.
To learn more about what we offer, please visit careers.thomsonreuters.com.
More information about Thomson Reuters can be found on thomsonreuters.com.
According to the U.S. Citizenship and Immigration Services (USCIS), the H-1B visa cap has been met for the 2015 fiscal year (October 1, 2014-September 30, 2015).